229 related articles for article (PubMed ID: 34676991)
21. Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs.
Alger E; Van Zyl M; Aiyegbusi OL; Chuter D; Dean L; Minchom A; Yap C
Res Involv Engagem; 2024 Jun; 10(1):63. PubMed ID: 38898479
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.
Stefanovic S; Wallwiener M; Karic U; Domschke C; Katic L; Taran FA; Pesic A; Hartkopf A; Hadji P; Teufel M; Schuetz F; Sohn C; Fasching P; Schneeweiss A; Brucker S
Support Care Cancer; 2017 Feb; 25(2):549-558. PubMed ID: 27747478
[TBL] [Abstract][Full Text] [Related]
23. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
24. The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials.
Coleman RL; Beck JT; Baranda JC; Jacobs I; Smoyer KE; Lee LJ; Askerova Z; McGinnis J; Ganti AK
Oncology; 2021; 99(7):444-453. PubMed ID: 33823518
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes in clinical studies of patients with hypertrophic cardiomyopathy.
Reza N; Day SM; Owens AT
Prog Cardiovasc Dis; 2023; 80():60-65. PubMed ID: 37625609
[TBL] [Abstract][Full Text] [Related]
26. Temporal Trends and Factors Associated With the Inclusion of Patient-Reported Outcomes in Heart Failure Randomized Controlled Trials: A Systematic Review.
Eliya Y; Averbuch T; Le N; Xie F; Thabane L; Mamas MA; Van Spall HGC
J Am Heart Assoc; 2021 Nov; 10(21):e022353. PubMed ID: 34689608
[TBL] [Abstract][Full Text] [Related]
27. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
[TBL] [Abstract][Full Text] [Related]
28. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
29. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
[TBL] [Abstract][Full Text] [Related]
30. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care).
Osawa T; Fujii Y; Kimura G; Kitamura H; Nagashima Y; Iizumi S; Osaka T; Tsubouchi R; Shinohara N
BMJ Open; 2023 Jul; 13(7):e070275. PubMed ID: 37495393
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.
Chadha J; Adashek JJ; Jim H; Kim Y; Semaan A; Chakiryan NH; Safa H; Hajiran A; Sexton W; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Clin Genitourin Cancer; 2022 Apr; 20(2):e158-e165. PubMed ID: 34974985
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
33. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
[TBL] [Abstract][Full Text] [Related]
34. Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps.
Afroz N; Gutzwiller FS; Mackay AJ; Naujoks C; Patalano F; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2020; 15():1789-1800. PubMed ID: 32801678
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; RodrÃguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
36. Integration of clinical and patient-reported outcomes in surgical oncology.
Macefield RC; Avery KN; Blazeby JM
Br J Surg; 2013 Jan; 100(1):28-37. PubMed ID: 23165422
[TBL] [Abstract][Full Text] [Related]
37. Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials.
Reaney M; Elash CA; Litcher-Kelly L
Diabetes Res Clin Pract; 2016 Jun; 116():54-67. PubMed ID: 27321317
[TBL] [Abstract][Full Text] [Related]
38. The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.
Rivera SC; Kyte DG; Aiyegbusi OL; Slade AL; McMullan C; Calvert MJ
Health Qual Life Outcomes; 2019 Oct; 17(1):156. PubMed ID: 31619266
[TBL] [Abstract][Full Text] [Related]
39. Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review.
Sparano F; Aaronson NK; Sprangers MAG; Fayers P; Pusic A; Kieffer JM; Cottone F; Rees J; Pezold M; Anota A; Charton E; Vignetti M; Wan C; Blazeby J; Efficace F
BMJ Support Palliat Care; 2019 Dec; 9(4):451-463. PubMed ID: 31719051
[TBL] [Abstract][Full Text] [Related]
40. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.
Kim J; Singh H; Ayalew K; Borror K; Campbell M; Johnson LL; Karesh A; Khin NA; Less JR; Menikoff J; Minasian L; Mitchell SA; Papadopoulos EJ; Piekarz RL; Prohaska KA; Thompson S; Sridhara R; Pazdur R; Kluetz PG
Clin Cancer Res; 2018 Apr; 24(8):1780-1784. PubMed ID: 29237718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
